Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

InvestorsWire.com brief · 46d ago · 1 min read · via cnbc.com

Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.

Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer. This story matters for Finance & Markets readers tracking finance. Reported by cnbc.com. Read the full original at the source link below.

Originally reported by cnbc.com. InvestorsWire.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily finance & markets signal

More from InvestorsWire.com

Related ventures